Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status Prescription; Discontinued
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 42571-131; 68554-0044; 65862-932; 31722-505; 0781-5893; 0597-0123; 65162-209; 64380-709; 33342-004; 65862-027; 0378-4050; 0378-4890; 70159-002; 65862-057; 53104-7546; 65862-933; 33342-238; 64220-102; 0597-0047
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyslipidaemia14.08.04.0150.012155%Not Available
Troponin increased13.04.01.0040.012155%Not Available
Drug resistance08.06.01.0050.009513%Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Connective tissue disorder15.06.01.006--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.0040.003171%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Lipohypertrophy23.07.01.005; 14.08.04.009--
Hepatic enzyme abnormal13.03.01.020--Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.003171%Not Available
Treatment failure08.06.01.0170.012684%Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Low birth weight baby18.04.02.0030.012155%Not Available
Oral disorder07.05.01.005--Not Available
Traumatic liver injury12.01.02.008; 09.01.08.010--Not Available
Hypertransaminasaemia09.01.02.005--Not Available
Acute kidney injury20.01.03.0160.018233%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.042543%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.012155%Not Available
Medication residue present13.15.01.0320.054698%Not Available
Enthesopathy15.07.01.0110.048621%Not Available
HIV test positive13.08.03.0060.018233%Not Available
Hyperadrenalism24.08.04.003; 14.11.01.028; 05.01.01.0050.018233%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.018233%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages